Legal Representation
Attorney
Brian P. Gregg
USPTO Deadlines
Next Deadline
1912 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-10-22)
Due Date
October 22, 2030
Grace Period Ends
April 22, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
29 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Apr 12, 2025 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Mar 25, 2025 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Mar 25, 2025 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Jan 22, 2025 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Oct 22, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Oct 22, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Aug 31, 2024 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | Loading... |
| Aug 14, 2024 | OPNR | P | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | Loading... |
| Aug 14, 2024 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Aug 6, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Aug 6, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jul 17, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jul 1, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 14, 2024 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Jun 14, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 14, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| May 14, 2024 | NREV | E | NOTICE OF REVIVAL - E-MAILED | Loading... |
| May 14, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| May 14, 2024 | PETG | O | PETITION TO REVIVE-GRANTED | Loading... |
| May 14, 2024 | PROA | I | TEAS PETITION TO REVIVE RECEIVED | Loading... |
| Nov 22, 2023 | RFNP | P | REFUSAL PROCESSED BY IB | Loading... |
| Nov 2, 2023 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Nov 2, 2023 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Nov 2, 2023 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Nov 1, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Oct 30, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 21, 2023 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Mar 17, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 16, 2023 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 040
Custom manufacture of polyclonal antibodies for pharmaceutical use; custom manufacture of biopharmaceuticals; processing of
biopharmaceutical materials for others; treatment of biopharmaceutical materials; processing of plant hormones being
phytohormones; processing of medicinal materials; processing of pharmaceutical preparations; custom manufacture of
pharmaceuticals; processing of pharmaceuticals; custom manufacture of pharmaceutical bispecific antibodies; processing of
chemical reagents
Class 042
Advisory services relating to technological research in the field of pharmaceutical manufacturing processes; advisory services
relating to scientific analysis in the field of nucleic acids; research relating to science, namely, scientific research; conducting of
technical feasibility studies, namely, conducting of feasibility studies in the field of new technologies; multiple nucleic acid scientific
analysis; multiple nucleic check, namely, materials testing; analysis of materials; materials testing and evaluation; chemical
analysis services for use in the testing of material; molecular analysis, namely, scientific analysis in the field of molecular biology;
advisory services relating to biotechnology; technical management advisory services relating to biotechnology, namely, scientific
research consulting, biotechnology consultancy services; biochemical analysis; advisory services relating to biochemistry
research; conducting early evaluations in the field of new pharmaceuticals; drug discovery services; design of new products for
others; technical advice relating to safety, namely, consumer product safety testing consultation; pharmaceutical research and
development; pharmaceutical products evaluation; clinical research in the field of medicines; services for assessing the efficiency
of pharmaceuticals, namely, testing of pharmaceuticals; testing of raw materials; fusion protein analysis being testing of raw
materials; computer programming services in the medical field; computer project management services relating to imaging
medical data; medicine research being medical research; scientific analysis and quality evaluation of medical product
development; pharmaceutical technology advisory service, namely, computer technology consultancy; pharmaceutical product
evaluation; providing scientific and medical information on the testing, inspection and research of medical products;
pharmaceutical product evaluation; scientific laboratory services relating to the production of bispecific antibody; bispecific
antibody drug development; double antibody reagent scientific research and development; evaluating of clinical trial progress,
namely, conducting clinical trials for others; clinical research, namely, conducting clinical trials for others; evaluation of product
development being product quality evaluation; product safety testing; quality assurance consultancy in the field of
pharmaceuticals; quality assessment being product testing; scientific research advisory services relating to chemical reagents;
evaluation of chemical syntheses being product quality evaluation
Additional Information
Pseudo Mark
DEVELOP PICK
Classification
International Classes
040
042